Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01235923 · ClinicalTrials.gov registry record · Phase 2

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

A Phase 2 study, sponsored by University of New Mexico.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01235923: Completed Phase 2 study, sponsored by University of New Mexico.

NCT01235923 is a Phase 2 study that has completed, run by University of New Mexico. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01235923, a Phase 2 study, has completed, sponsored by University of New Mexico.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. The investigators assessed weekly Epo dosing in preterm infants compared to standard three times weekly dosing.

Primary Outcome

retic count measured at study entry

Interventions

  • DRUG three times weekly Epo
  • DRUG weekly Epo

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2006-04
Est. Completion 2009-12
Phase Phase 2
University of New Mexico

168 total trials

What the finished NCT01235923 record still lists

NCT01235923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which three times weekly Epo is the first listed.

NCT01235923 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01235923 about?

NCT01235923 is a clinical study titled "Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants". Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. The investigators assess...

What is the current status of trial NCT01235923?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-04. Estimated completion is 2009-12.

What interventions are being tested in trial NCT01235923?

The interventions under investigation include: three times weekly Epo (DRUG), weekly Epo (DRUG).

Who is sponsoring clinical trial NCT01235923?

This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01235923's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01235923, the US trial registry maintained by the National Library of Medicine. NCT01235923 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.